Catalogue sales growth was 10.7% in the first half of the Cambridge group’s financial year with RabMAb, a suite of rabbit monoclonal antibodies, in huge demand.
China was a trail-blazer as its turnover grew just short of 30%.
For the year, Abcam expects turnover to increase by 10% on a constant currency basis and 30.4% on a reported basis.
"We have maintained revenue momentum delivering more than twice market revenue growth in the period,” said chief executive Alan Hirzel.
“Our award-winning web site, unique products and fast service enable Abcam to better serve researchers to achieve their mission faster.
“Overall, we continue to make good progress against our strategic and investment objectives and continue to see growth opportunities for Abcam."